Reshaping the Future of Lung Cancer Treatment With TROP2-Targeting ADCs and Rational Combinations

  Рет қаралды 996

PeerView Oncology

PeerView Oncology

Күн бұрын

Chair, Stephen V. Liu, MD, Sun Min Lim, MD, PhD, and Delvys Rodríguez Abreu, MD, PhD, discuss NSCLC in this CME activity titled “A Bold Frontier: Shattering the Limits of Conventional Therapies and Reshaping the Future of Lung Cancer Treatment With TROP2-Targeting ADCs and Rational Combinations.” For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/WFX865. CME credit will be available until October 8, 2024.

Пікірлер
Antibody Drug Conjugates: The end of chemotherapy | 2023 West Oncology Conference
27:03
Unlocking the Potential of Methylene Blue
35:14
MD Custom Rx
Рет қаралды 208 М.
NCCN Patient Webinar: Small Cell Lung Cancer
1:20:51
NCCN
Рет қаралды 9 М.
Antibody-drug Conjugates in the Clinic:
57:16
Certara
Рет қаралды 3,3 М.
The Cancer Expert: "This Common Food Is Making Cancer Worse!"
1:37:34
The Diary Of A CEO
Рет қаралды 7 МЛН
Metastatic Non-Small Cell Lung Cancer (NSCLC) Algorithm w/ Targetable Mutations- Dr. Jarushka Naidoo
19:12
OncBrothers: Practice-Changing Cancer Discussions
Рет қаралды 2,8 М.
Antibody Drug Conjugates for Cancer
56:32
Woo University
Рет қаралды 4,8 М.
Long-term Effects of Antipsychotics on the Brain
16:54
Dr. Josef
Рет қаралды 127 М.
The 2023 OncoAlert Colloquium (Breast Cancer)
3:37:30
OncoAlert 360
Рет қаралды 1,5 М.